Human Immunodeficiency Virus – Geographic Focus: China – HIV – China In-Depth – China

China has a high disease burden of human immunodeficiency virus (HIV), but patients are well managed by different classes of antiretroviral therapies (ARTs), including single-tablet regimens (e.g., bictegravir / emtricitabine / tenofovir alafenamide), fixed-dose NRTIs (e.g., emtricitabine / tenofovir), NRTIs (e.g., lamivudine, tenofovir), NNRTIs (e.g., efavirenz, nevirapine), protease inhibitors (e.g., lopinavir / ritonavir, darunavir / cobicistat), and integrase inhibitors (e.g., dolutegravir, raltegravir). The HIV therapy market of China is dynamic and growing fast as many effective ARTs—such as Merck’s Pifeltro and Gilead’s Biktarvy—boasting improved safety and tolerability, continue to launch. Several therapies, including tenofovir, lamivudine, efavirenz, abacavir, and lopinavir / ritonavir have enjoyed a high patient uptake in China owing to their free availability under the national free antiretroviral treatment program (NFATP) or improved patient accessibility due to inclusion in the NRDL. Despite the launch of novel therapies and improved drug-treatment rates, the HIV market of China is expected to grow moderately over the 2020-2030 period, owing to the price erosion resulting from the generic entry of many drugs and high discounts resulting from their inclusion in the volume-based procurement (VBP) programs.


  • How large is China’s drug-treatable HIV population, and how will the drug-treatment rate change during the forecast period?
  • Which are the most commercially relevant drugs in China’s HIV market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
  • What are the market access considerations for key therapies in the HIV pipeline in China? What sales / uptake could they secure in HIV? What are interviewed experts’ opinions of key emerging therapies?
  • What are the key drivers and constraints in the Chinese HIV market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release Date

September 2021



Primary Research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 infectious disease specialists.


Diagnosed prevalence of HIV in urban versus rural China. Clinically relevant and market-relevant drug-treatable populations.


10-year, annualized, drug-level sales and patient share of key anti-HIV therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions

Emerging Therapies

Phase III/PR: 3 drugs; Phase II: 2 drugs; coverage of select preclinical and Phase I products.

launch Related Market Assessment Reports